[go: up one dir, main page]

WO2019162756A3 - Liquid pharmaceutical compositions of anticancer drugs - Google Patents

Liquid pharmaceutical compositions of anticancer drugs Download PDF

Info

Publication number
WO2019162756A3
WO2019162756A3 PCT/IB2019/000068 IB2019000068W WO2019162756A3 WO 2019162756 A3 WO2019162756 A3 WO 2019162756A3 IB 2019000068 W IB2019000068 W IB 2019000068W WO 2019162756 A3 WO2019162756 A3 WO 2019162756A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
anticancer drugs
pharmaceutical compositions
liquid pharmaceutical
taste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/000068
Other languages
French (fr)
Other versions
WO2019162756A2 (en
Inventor
Swati NAGAR
Vijay Patel
Sandeep Pal
Sandip Mehta
Manish UMRETHIA
Jayanta Kumar Mandal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FTF Pharma Pvt Ltd
Original Assignee
FTF Pharma Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FTF Pharma Pvt Ltd filed Critical FTF Pharma Pvt Ltd
Publication of WO2019162756A2 publication Critical patent/WO2019162756A2/en
Publication of WO2019162756A3 publication Critical patent/WO2019162756A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cancer is one of the fast emerging diseases across the globe and the affected population includes patients from all age groups. Anticancer drugs are bitter in taste and therefore sometimes become unacceptable to patients because of its smell, taste, aftertaste and feeling in the mouth. Therefore there will always be a threat of rejection for the anticancer solid oral dosage forms by the patients. Additionally, solid oral dosage forms may not be suitable option for pediatric and geriatric patients or for the patients having swallowing difficulties. The present invention therefore describes liquid compositions of anticancer drugs which are palatable and acceptable to all types of patients' population.
PCT/IB2019/000068 2018-02-20 2019-02-20 Liquid pharmaceutical compositions of anticancer drugs Ceased WO2019162756A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821006376 2018-02-20
IN201821006376 2018-02-20

Publications (2)

Publication Number Publication Date
WO2019162756A2 WO2019162756A2 (en) 2019-08-29
WO2019162756A3 true WO2019162756A3 (en) 2019-10-31

Family

ID=65911206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/000068 Ceased WO2019162756A2 (en) 2018-02-20 2019-02-20 Liquid pharmaceutical compositions of anticancer drugs

Country Status (1)

Country Link
WO (1) WO2019162756A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021134647A1 (en) * 2019-12-31 2021-07-08 广州帝奇医药技术有限公司 Sustained release composition and preparation method therefor
LU103368B1 (en) 2022-12-29 2024-11-04 Renata Pharmaceuticals Ireland Ltd Pharmaceutical suspension of nilotinib

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
RU2347558C2 (en) * 2006-06-01 2009-02-27 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии имени Я.Р. Коваленко (ВИЭВ) Medication for treatment of dog's pyroplasmosis
US20130156853A1 (en) * 2010-09-01 2013-06-20 Peking University Liquid Compositions of Insoluble Drugs and Preparation Methods Thereof
WO2014041551A1 (en) * 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
WO2014147631A1 (en) * 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
US20170312281A1 (en) * 2014-10-29 2017-11-02 Therakind Ltd. Methotrexate formulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
RU2347558C2 (en) * 2006-06-01 2009-02-27 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии имени Я.Р. Коваленко (ВИЭВ) Medication for treatment of dog's pyroplasmosis
US20130156853A1 (en) * 2010-09-01 2013-06-20 Peking University Liquid Compositions of Insoluble Drugs and Preparation Methods Thereof
WO2014041551A1 (en) * 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
WO2014147631A1 (en) * 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
US20170312281A1 (en) * 2014-10-29 2017-11-02 Therakind Ltd. Methotrexate formulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200919, Derwent World Patents Index; AN 2009-F51221, XP002791708 *
HUTCHINSON M P ET AL: "Berenil in the treatment of Trypanosoma gambiense infection in man", TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, ELSEVIER, GB, vol. 56, no. 3, May 1962 (1962-05-01), pages 227 - 230, XP023298154, ISSN: 0035-9203, [retrieved on 19620501], DOI: 10.1016/0035-9203(62)90158-X *
SHI YANBIN ET AL: "Formulation and Optimization of Diminazene Aceturate Thermosensitive Hydrogel", LATIN AMERICAN JOURNAL OF PHARMACY (FORMERLY ACTA FARMACÉUTICA BONAERENSE), vol. 33, no. 3, January 2014 (2014-01-01), pages 398 - 402, XP009513588, ISSN: 0326-2383 *

Also Published As

Publication number Publication date
WO2019162756A2 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
Liczbiński et al. Molecular mechanism of curcumin action in signaling pathways: Review of the latest research
Pavithra Eugenol-a review
Lee Z944: a first in class T-type calcium channel modulator for the treatment of pain.
ES2902136T3 (en) Pharmaceutical compositions comprising an antiretroviral drug and a pharmacokinetic enhancer
ATE543489T1 (en) ORAL DOSAGE FORMS CONTAINING PROGESTERONE AND METHODS OF USE AND MANUFACTURING THEREOF
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MXPA05012810A (en) Memantine oral dosage forms.
WO2019162756A3 (en) Liquid pharmaceutical compositions of anticancer drugs
JP2006182679A (en) Preventing and treating agent of stress gastritis
Dabaghian et al. An overview on multi-ingredient memory enhancers and anti-Alzheimer’s formulations from traditional Persian pharmacy
JP7111375B2 (en) Learning and memory enhancing composition
JP4904795B2 (en) Fatigue improver composition
DE502005008500D1 (en) USE OF LAVENDER OIL FOR PROPHYLAXIS AND TREATMENT OF SOMATIZING DISORDERS AND POSTAL DISEASE DISEASE
RU2557962C1 (en) Pharmaceutical composition of methisoprinol for oral administration
CA2917081C (en) Use of adsorbed drone brood homogenate and of vitamin d3 or d group vitamins and/or active metabolites thereof for the prophylaxis and treatment of viral diseases
CN100579535C (en) Immune function and improvements related to it
Ahmed Effect of Cinnamon Oil and Scorpion Venom on Oral Squamous Cell Carcinoma Cell Line (In vitro study)
UA117416C2 (en) MEDICINAL IN THE FORM OF SYRUP FOR THE ORAL APPLICATION OF A WIDE SPECTRUM OF ACTION
JP2016017076A (en) Oral liquid agent for seven to fourteen year olds comprising taurine as well as carrot, ophiopogon tuber, licorice, jujube, cinnamon bark and royal jelly
Sevlani et al. Oral Sub Mucous Fibrosis: A Review.
CN103169744B (en) A pharmaceutical composition for treating cerebral ischemia and cerebral infarction
Moafa Formulation, optimization and evaluation of piperine loaded nanovesicles medicated drug delivery for the treatment of cancer
JP2011051942A (en) Therapeutic agent for dementia
Ghani et al. EFFECT OF CINNAMON OIL AND SCORPION VENOM ON ORAL SQUAMOUS CELL CARCINOMA CELL LINE (IN VITRO STUDY)
Hwang Ethanol Extract of Smilax glabra Induces Apoptotic Cell Death in Human YD10B Oral Squamous Cell Carcinoma Cells

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19713559

Country of ref document: EP

Kind code of ref document: A2